Nicotinamide mononucleotide supplementation rescues mitochondrial and

DesignPreclinical aged-mouse ovarian intervention with histology, electron microscopy, transcriptomics and metabolic analyses

PopulationAging female mice

SampleMultiple age and treatment groups; see publication

InterventionNMN supplementation in aged mice

EndpointsOvarian NAD+; Ovarian atrophy and follicle counts; Oocyte quantity and quality; Hormones and antioxidant factors; Inflammatory markers; Granulosa-cell mitochondria and lipid droplets; Transcriptomic pathways

What the publication reported

This 2024 mouse study investigated how NMN affects aging ovaries at the tissue, cellular and transcriptomic levels.

NMN increased ovarian NAD+, reduced ovarian atrophy in the model, altered follicle and oocyte measures, and was associated with improved mitochondrial and energy-metabolism signals and lower inflammatory markers.

The findings strengthen preclinical ovarian-aging mechanisms but do not show that NMN improves fertility or ovarian reserve in women.

Key findings

Ovarian NAD+ increased after NMN treatment.
Ovarian atrophy and follicle/oocyte measures improved in the aged-mouse model.
Mitochondrial morphology and energy-metabolism pathways changed.
Pro-inflammatory markers decreased while antioxidant-related measures improved.

What it cannot establish

Animal study only.
Transcriptomic and morphologic endpoints are not clinical fertility outcomes.
Mouse ovarian aging differs from human reproductive aging.
No randomized human reproductive trial was conducted.

HealthspanX claim boundary: This study does not establish improved ovarian reserve, fertility, egg quality, pregnancy or reproductive lifespan in women.

Source identifiers

DOI: 10.1002/mco2.727
PubMed: PMID 39355508
Trial registration: Not applicable.
Publication type: Preclinical animal study
Publication: MedComm, 2024. 5(10):e727

Transparency

Funding: Supported by the National Natural Science Foundation of China, National High-Level Hospital Clinical Research Funding, National Key Research and Development Program, and CAMS Innovation Fund for Medical Sciences.
Declared interests: See source publication for competing-interest declaration.

HealthspanX observation: The mechanistic ovarian-aging evidence is increasingly consistent across mouse studies, but translation to women remains unproven.

Interpretive status: Mechanistic contextDetailed aged-mouse ovarian study with transcriptomic and mitochondrial data; cannot establish human fertility or ovarian-reserve efficacy.

Continue reviewing

Return to the complete evidence library.

Evidence Center Ultra Pure NMN

Source fields verified 20 September 2026